Business Context and Reporting Period
This Form 8-K Current Report was filed by Ocular Therapeutix, Inc. on September 20, 2021. The filing addresses corporate governance changes, specifically the election of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
The primary material change reported is the appointment of Merilee Raines to the Board of Directors and the Audit Committee, effective September 20, 2021. This appointment filled a vacancy, bringing the total number of Board members to eight.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding business operations. It details the background of the new director, Ms. Raines, noting her prior experience as CFO of IDEXX Laboratories, Inc., and her board service at Watts Water Technologies, Inc., and TransMedics Group, Inc.
Regarding compensation, Ms. Raines received an option to purchase 36,000 shares of common stock at an exercise price of $10.02 per share, based on the closing price on the Effective Date. She will otherwise be compensated in the same manner as other non-employee directors.
A standard Indemnification Agreement was entered into, which may require the Company to indemnify Ms. Raines for expenses, judgments, fines, and settlement amounts incurred in actions arising from her service as a director.
Investor Verification Checklist
- Verify the total number of Board members is now eight with no vacancies.
- Confirm the grant of 36,000 stock options to Merilee Raines at an exercise price of $10.02 per share.
- Review the Company's proxy statement filed on April 29, 2021, for details on standard director compensation.
- Note the existence of an Indemnification Agreement filed as Exhibit 10.12 to the Company's 2014 Form S-1.